Page last updated: 2024-12-05

1,3-butadiene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-Butadiene is a colorless, flammable gas at room temperature with a slightly sweet odor. It is a highly reactive and versatile organic compound that is used as a building block in the production of synthetic rubber, plastics, and other chemicals. 1,3-Butadiene is produced through the steam cracking of hydrocarbons, primarily naphtha, and is also a byproduct of the production of other chemicals, such as ethylene and propylene. 1,3-Butadiene is a key component in the manufacture of synthetic rubber, particularly styrene-butadiene rubber (SBR), which is used in tires, belts, and other rubber products. It is also used in the production of acrylonitrile butadiene styrene (ABS) plastics, which are used in a wide variety of applications, such as automotive parts, appliances, and toys. 1,3-Butadiene is a known human carcinogen, and exposure to high levels of the compound can cause respiratory problems, dizziness, and headaches. Because of its industrial importance and potential health effects, 1,3-butadiene is a subject of significant scientific research.'

buta-1,3-diene : A butadiene with unsaturation at positions 1 and 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7845
CHEMBL ID537970
CHEBI ID39478
CHEBI ID39479
MeSH IDM0099583

Synonyms (88)

Synonym
1,3-butadiene
.alpha.,.gamma.-butadiene
106-99-0
buta-1,3-diene
inchi=1/c4h6/c1-3-4-2/h3-4h,1-2h
vinyl ethylene
butadien [polish]
un 1010
butadiene-1,3-uninhibited
butadiene ,
alpha-gamma-butadiene
buta-1,3-dieen [dutch]
nci-c50602
butadiene, 1,3-
biethylene
butadieen [dutch]
butadiene monomer
erythrene
hsdb 181
pyrrolylene
buta-1,3-dien [german]
ccris 99
einecs 203-450-8
vinylethylene
CHEBI:39478 ,
ch2=ch-ch=ch2
alpha,gamma-butadiene
bivinyl
divinyl
1,3-butadien
buta-1,3-dien
1,3-butadiene, >=99%
B0675
CHEMBL537970
9003-17-2
1,3-butadiene, homopolymer
AKOS007930655
68514-37-4
buta-1,3-dieen
ec 203-450-8
unii-jsd5fgp5vd
butadien
jsd5fgp5vd ,
butadieen
FT-0606587
butadiene [inci]
1,3-butadiene [hsdb]
1,3-butadiene [mi]
1,3-butadiene [iarc]
1,3 butadiene
ch2=chch=ch2
25339-57-5
B4358
B4835
B4359
DTXSID3020203 ,
1,3-butadiene, >=99.6%
mfcd00008659
1,3-butadiene, puriss., >=99.5% (gc)
1,3-butadiene, purum, >=98.0%
1,3-butadiene (ca. 15% in hexane)
1,3-butadiene 95%
1,3-butadiene 200 microg/ml in methanol
ch22ch1ch2ch2
alpha,<>-butadiene
130983-70-9
1983-06-8
1,3-butadiene (ca. 15% in toluene)
1,3-butadiene 100 microg/ml in methanol
Q161503
1,3-butadiene 250 microg/ml in n,n-dimethylacetamide
1,3-butadiene 150 microg/ml in n,n-dimethylacetamide
1,3-butadiene 400 microg/ml in n,n-dimethylacetamide
1,3-butadiene 10 microg/ml in n,n-dimethylacetamide
1,3-butadiene 50 microg/ml in n,n-dimethylacetamide
1,3-butadiene (ca. 13% in tetrahydrofuran, ca. 2mol/l)
1,3-butadiene (~15per cent by weight in toluene)
1,3-butadiene-2,3-d2
26952-74-9
dtxcid10203
1,3-butadiene (iarc)
butadiene-1,3
alpha, gamma-butadiene
butadiene-1, 3, stabilized
butadienes, stabilized
1,3-butadiene, (stabilized)
chebi:39479
1,3-butadiene 1000 microg/ml in methanol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"3-Butene-1,2-diol (butenediol), a major metabolite of 1,3-butadiene (butadiene), can undergo either detoxification or biotransformation to potentially toxic metabolites, including 3,4-epoxy-1,2-butanediol and hydroxymethylvinyl ketone (HMVK)."( Effect of n-hexane on the disposition and toxicity of the 1,3-butadiene metabolite 3-butene-1,2-diol.
Bird, MG; Iba, MM, 2007
)
0.83
" The chronic ReV value, along with a unit risk factor developed by the TCEQ, will be used to evaluate ambient air monitoring data so that the general public is protected against adverse health effects from chronic exposure to BD."( A chronic reference value for 1,3-butadiene based on an updated noncancer toxicity assessment.
Curry, AL; Grant, RL; Haney, J; Honeycutt, M, 2010
)
0.65
" That is, this paradigm would be protective of any mechanism that resulted in adverse effects typically observed in guideline studies, because product safety assessment is based upon observed apical effects to drive an overall NOAEL that is the basis to set reference doses for a risk assessment."( Is the current product safety assessment paradigm protective for epigenetic mechanisms?
Alyea, RA; Gollapudi, BB; LeBaron, MJ; Moore, NP; Rasoulpour, RJ,
)
0.13
"These adverse apical effects are the culmination of all molecular events, regardless of mechanism and may include alterations in the epigenome secondary to the actions of those mechanism(s)."( Is the current product safety assessment paradigm protective for epigenetic mechanisms?
Alyea, RA; Gollapudi, BB; LeBaron, MJ; Moore, NP; Rasoulpour, RJ,
)
0.13
" The Ames test results showed that CHB induced point mutation but not frameshift mutation, whereas the toxic effects of CBO made it difficult to reliably assess the mutagenic potential of CBO in the two strains."( Cytotoxicity, genotoxicity, and mutagenicity of 1-chloro-2-hydroxy-3-butene and 1-chloro-3-buten-2-one, two alternative metabolites of 1,3-butadiene.
An, J; Elfarra, AA; Liu, XJ; Yu, YX; Zeng, FM; Zhang, XY, 2013
)
0.59
" EBD and its analog with a hydroxy substituent at C1 were found to be highly toxic to FANCD2-deficient chicken and human cells."( An unexpected butadiene diolepoxide-mediated genotoxicity implies alternative mechanism for 1,3-butadiene carcinogenicity.
Carro, S; Gold, A; Nakamura, J; Zhang, Z, 2021
)
0.84

Pharmacokinetics

ExcerptReferenceRelevance
" In order to translate these results into conditions of human exposure, we developed a physiologically based pharmacokinetic (PBPK) model, which is presented here."( A pharmacokinetic model to describe toxicokinetic interactions between 1,3-butadiene and styrene in rats: predictions for human exposure.
Baur, C; Csanády, GA; Filser, JG; Johanson, G; Kessler, W; Kreuzer, PE; Stei, P, 1993
)
0.52
" A physiologically based pharmacokinetic model of the uptake, tissue distribution, and metabolism of butadiene was constructed to determine if the biochemical kinetic constants obtained from in vitro studies are consistent with the observed in vivo uptake and metabolism."( Species differences in the production and clearance of 1,3-butadiene metabolites: a mechanistic model indicates predominantly physiological, not biochemical, control.
Kohn, MC; Melnick, RL, 1993
)
0.53
" A physiologically based pharmacokinetic (PBPK) model was developed to describe the simultaneous disposition of BD and styrene in mice coexposed by inhalation."( Pharmacokinetic model describing the disposition of butadiene and styrene in mice.
Bond, JA; Leavens, TL, 1996
)
0.29
" To achieve this objective, known pathways of 1,2-epoxy-3-butene (butadiene monoepoxide; BMO) and BDE metabolism were incorporated into a physiologically based pharmacokinetic model by scaling rates determined in vitro."( Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats.
Bond, JA; Medinsky, MA; Schlosser, PM; Sweeney, LM, 1997
)
0.55
" As a tutorial, we first simplify a 2-compartment pharmacokinetic model by symbolic lumping."( Lumping in pharmacokinetics.
Bois, FY; Brochot, C; Tóth, J, 2005
)
0.33
"Physiologically based pharmacokinetic (PBPK) models have proven to be successful in integrating and evaluating the influence of age- or gender-dependent changes with respect to the pharmacokinetics of xenobiotics throughout entire lifetimes."( A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan.
Beaudouin, R; Brochot, C; Micallef, S, 2010
)
0.36
" Physiologically based pharmacokinetic (PBPK) models provide realistic descriptions of xenobiotics' absorption, distribution, metabolism, and excretion processes."( Modeling Pharmacokinetics.
Bois, FY; Brochot, C, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"To investigate the genotoxicity of gaseous toxicants carbon monoxide (CO) and 1,3-butadiene in vitro, a novel combination technology-the in vitro γH2AX high content screening assay combined with air-liquid interface system (ALIS) was established."( Genotoxicity evaluation of carbon monoxide and 1,3-butadiene using a new joint technology: the in vitro γH2AX HCS assay combined with air-liquid interface system.
Chen, H; Hou, H; Hu, Q; Liu, Y; Wang, A; Zhang, S, 2019
)
1

Bioavailability

ExcerptReferenceRelevance
"The adduct formed by the reaction of 1,3-butadiene monoxide, a major metabolite of the mutagen and carcinogen 1,3-butadiene, with the N-terminal valine of haemoglobin was used as a dosimeter for the bioavailability of reactive metabolites."( Biological monitoring of 1,3-butadiene: species differences in haemoglobin binding in rat and mouse.
Albrecht, OE; Filser, JG; Neumann, HG, 1993
)
0.86
" However, studies on how they interact to influence their bioavailability are scarce."( Insight into Bioaccumulation of Decabromodiphenyl Ethane in
Fu, M; Han, Y; Hu, S; Ling, S; Peng, C; Qiao, Z; Tan, J; Zhang, W; Zhou, S, 2023
)
0.91

Dosage Studied

1,3-butadiene is linked to an increased cancer risk of 10%. The methodology was evaluated with Hb samples obtained by reacting butadiene monoepoxide (BMO) with blood and by dosing BMO to mice.

ExcerptRelevanceReference
"The traditional multistage (MS) model of carcinogenesis implies several empirically testable properties for dose-response functions."( An exact analysis of the multistage model explaining dose-response concavity.
Cox, LA, 1995
)
0.29
" The working group identified a series of urgent research needs to provide the appropriate data for the application of the parallelogram model, such as identification of metabolic pathways in different rodent species and humans, metabolic studies in mice, rats and humans considering metabolic polymorphisms, studies of adducts to DNA and hemoglobin especially of DEB and other butadiene metabolites in rodents and humans, studies of mutational spectra (mutational fingerprinting) in somatic and germinal cells, confirmation of the human hprt mutation data, conformation of the rodent malformation data, dose-response studies in rodent germ cell tests and studies on repair kinetics of mono-adducts induced by EB as opposed to repair of cross-links produced by DEB."( 1,3-Butadiene working group report.
Adler, ID; Cochrane, J; Osterman-Golkar, S; Skopek, TR; Sorsa, M; Vogel, E, 1995
)
1.73
" The methodology was evaluated with Hb samples obtained by reacting butadiene monoepoxide (BMO), the primary reactive metabolite of 1,3-butadiene, with blood and by dosing BMO to rats and mice."( Biological monitoring of butadiene exposure by measurement of haemoglobin adducts.
Megens, HJ; Richardson, KA; van Sittert, NJ; Webb, JD, 1996
)
0.5
" "Comprehensive Realism" is an emerging quantitative weight-of-evidence based risk assessment methodology for both cancer and noncancer health effects which utilizes probability distributions and decision analysis techniques to reflect more of the available human and animal dose-response data."( Using PBPK modeling and comprehensive realism methodology for the quantitative cancer risk assessment of butadiene.
Hays, SM; Reitz, RH; Sielken, RL, 1996
)
0.29
" The dose-response for BMO followed a second order curve at this time interval, with maximum MN induction at the dose of 186 mumol/kg and lower induction of higher doses."( Germ cell mutagenicity of three metabolites of 1,3-butadiene in the rat: induction of spermatid micronuclei by butadiene mono-, di-, and diolepoxides in vivo.
Lähdetie, J; Peltonen, K; Sjöblom, T, 1997
)
0.55
" Within this project a dominant lethal test and a heritable translocation test were performed with male mice to study the dose-response relationships for the respective endpoints."( Dose response study for 1,3-butadiene-induced dominant lethal mutations and heritable translocations in germs cells of male mice.
Adler, ID; Filser, J; Gonda, H; Schriever-Schwemmer, G, 1998
)
0.61
" The methods developed in this work provide the means to study accumulation, repair and dose-response relationships of BD-DNA adducts in vivo."( Quantitative analysis of 1,3-butadiene-induced DNA adducts in vivo and in vitro using liquid chromatography electrospray ionization tandem mass spectrometry.
Chiang, SY; Swenberg, JA; Walker, VE, 1998
)
0.6
" Survival adjusted tumor rates in mice were fit to a Weibull model for estimation of the shape of the dose-response curves, estimation of ED10 values (the estimated exposure concentration associated with an increased cancer risk of 10%) and comparison of these parameters with those for 1,3-butadiene."( Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice.
Chou, BJ; Grumbein, SL; Melnick, RL; Miller, RA; Portier, CJ; Roycroft, JH; Sills, RC, 1999
)
0.72
" Supra-linear dose-response curves were observed in BD-exposed mice, indicating a higher efficiency of mutant induction at lower concentrations of BD."( Mutagenicity of 1,3-butadiene at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats.
Bauer, MJ; Chen, T; Heflich, RH; Henderson, RF; Meng, Q; Reilly, AA; Walker, DM; Walker, VE, 1999
)
0.65
" Generally, the brain tumor responses were considered equivocal, because the characteristics of potential neurocarcinogenic agents (such as statistically significant increased incidences, decreased latency and/or survival, and demonstration of dose-response relationships) were not observed."( Examination of low-incidence brain tumor responses in F344 rats following chemical exposures in National Toxicology Program carcinogenicity studies.
Boorman, GA; Hailey, JR; Haseman, JK; Melnick, RL; Neal, J; Sills, RC,
)
0.13
" The dose-response for mutations induced at the cII locus was essentially equal after DEB exposure of BBM1 and BBR1 fibroblasts."( Micronuclei and gene mutations in transgenic big Blue((R)) mouse and rat fibroblasts after exposure to the epoxide metabolites of 1, 3-butadiene.
Erexson, GL; Tindall, KR, 2000
)
0.31
" Urinary excretion of radioactivity, following dosing with DMDTC and exposure to 200 ppm C-14 butadiene for 6 h, was markedly reduced in rats, but increased in mice."( The influence of co-exposure to dimethyldithiocarbamate on butadiene metabolism.
Green, T; Moore, R; Toghill, A, 2001
)
0.31
"01 (1%) from a lifetime continuous exposure to 1,3-butadiene based on a linear dose-response model and the cumulative 1,3-butadiene dose metric (ppm-years)."( Dose-response implications of the University of Alabama study of lymphohematopoietic cancer among workers exposed to 1,3-butadiene and styrene in the synthetic rubber industry.
Sielken, RL; Valdez-Flores, C, 2001
)
0.78
" The dose-response relationship for the formation of adduct G4 was approximately linear for all tissues studied for both rats and mice exposed in the 1-20 ppm range."( Dose responses for DNA adduct formation in tissues of rats and mice exposed by inhalation to low concentrations of 1,3-[2,3-[(14)C]-butadiene.
Booth, ED; Kilgour, JD; Robinson, SA; Watson, WP, 2004
)
0.32
"The method can be applied to predict the risk of carcinogenic agents for which dose-response data exist and no health-based limit value can be established."( [A simple method for risk assessment and its application to 1,3-butadiene].
Bertazzi, PA; Pesatori, AC; Zocchetti, C,
)
0.37
" In particular, these guidelines encourage the use of mechanistic data in support of dose-response characterization at doses below those at which an increase in tumor frequency over background levels might be detected."( Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston, RJ, 2007
)
0.64
" Exposure estimates were updated and an exposure estimate validation study as well as dose-response modeling were conducted by these researchers."( Development of a unit risk factor for 1,3-butadiene based on an updated carcinogenic toxicity assessment.
Curry, AL; Grant, RL; Haney, J; Honeycutt, M, 2009
)
0.62
" A number of factors related to metabolism can also contribute to nonlinearity in the dose-response relationship, including enzyme induction and inhibition, depletion of tissue glutathione, and saturation of oxidative metabolism."( 1,3-Butadiene: I. Review of metabolism and the implications to human health risk assessment.
Albertini, RJ; Gargas, ML; Kirman, CR; Sweeney, LM, 2010
)
1.8
" The MOAs for BD carcinogenesis will be used to guide key decisions made in the quantitative cancer dose-response assessment."( 1,3-Butadiene: III. Assessing carcinogenic modes of action.
Albertini, RA; Gargas, ML; Kirman, CR, 2010
)
1.8
" A meta-analysis was conducted in which the available dose-response data from rats and mice were normalized using an internal dose estimate (DEB in blood) that is causally related to ovarian toxicity."( Quantitative human health risk assessment for 1,3-butadiene based upon ovarian effects in rodents.
Grant, RL; Kirman, CR, 2012
)
0.64
" Dose-response analyses from toxicity studies from government reports were evaluated and the most sensitive cancer and noncancer endpoints were selected."( Tobacco smoke-related health effects induced by 1,3-butadiene and strategies for risk reduction.
Bos, PM; Soeteman-Hernández, LG; Talhout, R, 2013
)
0.65
" In HL60 cells exposed for 3 h to 0-10 μM DEB, overlapping dose-response curves suggested a direct relationship between 1,4-bis-(guan-7-yl)-2,3-butanediol crosslink adduct formation (R = 0."( 1,3-Butadiene metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22) translocations in human cells.
Albertini, RJ; Carter, EW; Degner, A; Nicklas, JA; Tretyakova, N; Walker, DM; Walker, VE, 2019
)
1.96
" Select F1 offspring (1/sex/litter) were dosed 7 days (postnatal days 21-27 or 28-34), then necropsied."( A reproductive and developmental toxicity screening study of 1,3-butadiene in Sprague-Dawley rats.
Barranco, WT; Budinsky, R; Cagen, S; Erraguntla, N; Kirman, CR; Koehler, MW; Marty, MS; North, C; Rushton, EK; Shen, H, 2021
)
0.86
" Using these methods, the dose-response relationships in mice and rats exhibit improved concordance, and result in subchronic and chronic inhalation reference values of 29 and 10 ppm, respectively, for BD."( Use of biomarker data and metabolite relative potencies to support derivation of noncancer reference values based on the reproductive and developmental toxicity effects of 1,3-butadiene.
Erraguntla, N; Hays, SM; Kirman, CR; North, CM; Shen, H; Tretyakova, NY, 2022
)
0.92
" EPA's cancer dose-response assessment for BD was published in 2002 and was primarily based on a study on workers exposed to BD in the North American synthetic Styrene-Butadiene Rubber (SBR) Industry developed by the University of Alabama at Birmingham (UAB)."( An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene.
Budinsky, R; Cagen, S; Erraguntla, N; Kirman, CR; Valdez-Flores, C, 2022
)
0.93
" We observed positive dose-response relationships of DHBMA level with glucose homeostasis indices and ALP levels, as well as with the risks of prediabetes and diabetes (all P < 0."( Associations of urinary 1,3-butadiene metabolite with glucose homeostasis, prediabetes, and diabetes in the US general population: Role of alkaline phosphatase.
Chen, W; Feng, X; Liang, R; Shi, D; Wang, B; Yang, M; Yu, L; Zhang, Y; Zhou, M, 2023
)
1.22
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
butadiene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID603952In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID603951In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID603950In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (794)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (8.19)18.7374
1990's218 (27.46)18.2507
2000's222 (27.96)29.6817
2010's211 (26.57)24.3611
2020's78 (9.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.04 (24.57)
Research Supply Index6.73 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index110.36 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (0.72%)5.53%
Reviews80 (9.66%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other742 (89.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]